Next Article in Journal
Can Nuclear Imaging of Activated Macrophages with Folic Acid-Based Radiotracers Serve as a Prognostic Means to Identify COVID-19 Patients at Risk?
Next Article in Special Issue
Synthesis, Biological, and Computational Evaluation of Antagonistic, Chiral Hydrobenzoin Esters of Arecaidine Targeting mAChR M1
Previous Article in Journal
The Role of Adaptogens in Prophylaxis and Treatment of Viral Respiratory Infections
Previous Article in Special Issue
New Insights into the Stereochemical Requirements of the Bombesin BB1 Receptor Antagonists Binding
Review

Tumor Immunotherapy Using A2A Adenosine Receptor Antagonists

1
iHuman Institute, ShanghaiTech University, Shanghai 201210, China
2
School of Life Science and Technology, ShanghaiTech University, Shanghai 201210, China
3
Department of Integrated Structural and Computational Biology, Scripps Research, La Jolla, CA 92037, USA
*
Author to whom correspondence should be addressed.
Pharmaceuticals 2020, 13(9), 237; https://doi.org/10.3390/ph13090237
Received: 14 August 2020 / Revised: 31 August 2020 / Accepted: 2 September 2020 / Published: 8 September 2020
(This article belongs to the Special Issue GPCRs: Ligands and beyond 2022)
The A2A adenosine receptor (A2AAR) plays critical roles in human physiology and pathophysiology, which makes it an important drug target. Previous drug-discovery efforts targeting the A2AAR have been focused on the use of A2AAR antagonists for the treatment of Parkinson’s disease. More recently, the A2AAR has attracted additional attention for its roles in immuno-oncology, and a number of A2AAR antagonists are currently used as lead compounds for antitumor drugs in both preclinical models and clinical trials. This review surveys recent advances in the development of A2AAR antagonists for cancer immunotherapy. The therapeutic potential of representative A2AAR antagonists is discussed based on both animal efficacy studies and clinical data. View Full-Text
Keywords: GPCR; immuno-oncology; Parkinson’s disease; drug binding modes; cancer therapy GPCR; immuno-oncology; Parkinson’s disease; drug binding modes; cancer therapy
Show Figures

Figure 1

MDPI and ACS Style

Zhang, J.; Yan, W.; Duan, W.; Wüthrich, K.; Cheng, J. Tumor Immunotherapy Using A2A Adenosine Receptor Antagonists. Pharmaceuticals 2020, 13, 237. https://doi.org/10.3390/ph13090237

AMA Style

Zhang J, Yan W, Duan W, Wüthrich K, Cheng J. Tumor Immunotherapy Using A2A Adenosine Receptor Antagonists. Pharmaceuticals. 2020; 13(9):237. https://doi.org/10.3390/ph13090237

Chicago/Turabian Style

Zhang, Jinfeng, Wenzhong Yan, Wenwen Duan, Kurt Wüthrich, and Jianjun Cheng. 2020. "Tumor Immunotherapy Using A2A Adenosine Receptor Antagonists" Pharmaceuticals 13, no. 9: 237. https://doi.org/10.3390/ph13090237

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop